Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
R940343 · 1 trial · 1 indication
Change from baseline in pre-BD FEV1 (% predicted) at Week 8.
| Arm | Type | Description |
|---|---|---|
| R940343 2mg, 2 puffs bid | ACTIVE_COMPARATOR | R343 2mg, 2 puffs bid |
| Placebo | PLACEBO_COMPARATOR | - |
| R940343 1mg, 1 puff bid | ACTIVE_COMPARATOR | R343 1mg, 1 puff bid |
| Name | Type | Description |
|---|---|---|
| Placebo | DRUG | 1 puff bid or 2 puffs bid |
| R940343 1mg | DRUG | R343 1mg, 1 puff bid |
| R940343 2mg | DRUG | R343 2mg, 2 puffs bid |
Inclusion Criteria: * Clinical history of asthma * Ability to perform spirometry Exclusion Criteria: * Chronic obstructive pulmonary disease or bronchiectasis * Upper or lower respiratory infection
R940343 is an investigational small molecule being studied for the treatment of mild to moderate asthma. It is administered via inhalation. The drug is currently in Phase 2 clinical development and is not approved by regulatory authorities.
R940343 is being developed by Rigel Pharmaceuticals, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol RIGL. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational drug.
R940343 is in Phase 2 clinical development. It has completed one Phase 2 trial, which was a randomized, double-blind, placebo-controlled study. The drug remains investigational and has not received regulatory approval for any use.
R940343 has been studied in one completed Phase 2 clinical trial, identified as NCT01591044. This trial was a safety and efficacy study of inhaled R940343 in patients with mild to moderate asthma, enrolling 301 participants in the United States and Canada.
R940343 is the primary name for this investigational drug. No alternative names have been reported in clinical trial records. It is a small molecule developed by Rigel Pharmaceuticals for the treatment of asthma.